
    
      A.To obtain preliminary data on the safety and tolerability of ranibizumab (0.5 mg)in
      patients with new or progressive neovascularization of the iris or angle due to retinal
      ischemic diseases in addition to treatment with PRP using the incidence and severity of
      adverse events identified by subjenc reporting vital signs, and ocular examition.

      B.To assess the proportion of patients who fail to experience regression of iris and angle
      neovascularization documented by the clinical examination, iris florescein angiography and
      gonioscopic evaluation.
    
  